LLY
ELI LILLY & Co
NYSE · Healthcare · Drug Manufacturers - General · US
$1,414.27
+0.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 86.5B | 65.2B | 45.0B | 34.1B | 28.5B |
| Cost of Revenue | 14.1B | 11.1B | 8.4B | 7.1B | 6.6B |
| Gross Profit | 72.3B | 54.1B | 36.6B | 27.0B | 21.9B |
| Operating Expenses | |||||
| R&D Expense | 15.4B | 13.3B | 11.0B | 9.3B | 7.2B |
| SG&A Expense | 12.6B | 11.1B | 8.6B | 6.9B | 6.1B |
| General & Admin Expense | 3.1B | — | 8.6B | 6.9B | 6.1B |
| Selling & Marketing Expense | — | — | 200.0K | — | — |
| Other Expenses | 4.5B | — | — | — | — |
| Total Operating Expenses | 32.5B | 24.4B | 19.6B | 16.3B | 13.3B |
| Cost and Expenses | 46.6B | 35.5B | 28.0B | 23.3B | 19.9B |
| Operating Income (EBIT) | 39.8B | 29.7B | 17.0B | 10.8B | 8.7B |
| Non-Operating | |||||
| Interest Income | — | 153.3M | 175.2M | 173.6M | 62.8M |
| Interest Expense | 1.2B | 795.3M | 780.6M | 485.9M | 331.6M |
| Net Interest Income | (1.2B) | (642.0M) | (605.4M) | (312.3M) | (268.8M) |
| Other Non-Op Income/Expense | (5.1B) | (4.0B) | (4.4B) | (4.2B) | (1.8B) |
| Non-Operating Income (excl Interest) | (2.7B) | — | — | 3.7B | 1.5B |
| EBT (Pre-Tax Income) | 34.8B | 25.7B | 12.7B | 6.6B | 6.8B |
| Income Tax Expense | 7.2B | 5.1B | 2.1B | 1.3B | 561.6M |
| Bottom Line | |||||
| Net Income | 27.6B | 20.6B | 10.6B | 5.2B | 6.2B |
| Earnings from Cont. Ops | 27.6B | 20.6B | 10.6B | 5.2B | 6.2B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 27.6B | 20.6B | 10.6B | 5.2B | 6.2B |
| Per Share | |||||
| Basic EPS | $30.89 | $23.07 | $11.76 | $5.83 | $6.57 |
| Diluted EPS | $30.81 | $22.95 | $11.71 | $5.80 | $6.57 |
| Revenue Per Share | $96.94 | $72.58 | $50.01 | $37.94 | $30.04 |
| Shares | |||||
| Basic Shares Outstanding | 891.9M | 898.0M | 900.6M | 899.4M | 950.2M |
| Diluted Shares Outstanding | 893.4M | 898.0M | 904.1M | 903.3M | 950.2M |
| Profitability Metrics | |||||
| EBITDA | 44.8B | 31.7B | 18.8B | 8.6B | 8.7B |
| D&A | 2.2B | 2.0B | 1.8B | 1.5B | 1.5B |
| EBIT | 42.6B | 29.7B | 17.0B | 7.0B | 7.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026